1Lin LL, Grigsby PW, Powell MA, et al. Definitive radiotherapy in the management of isolated vaginal recurrences of endometrial cancer[ J]. Int J Radiat Oneol Biol Phys,2005,63:500- 504.
2Fleisch MC, Pantke P, Beckmann MW, et al. Predictors for long-term survival after interdisciplinary salvage surgery for ad- vanced or recurrent gynecologic cancers [ J ]. J Surg Oncol, 2007,95:476-484.
3Boruta DM 2nd, Gehrig PA, Fader AN, et al. Management of women with uterine papillary serous cancer: a Society of Gynecologic Oncology (SGO) review [ J ]. Gynecol Oncol, 2009, 115 : 142-153.
4Fader AN, Boruta D, Olawaiye AB, et al. Uterine papillary serous carcinoma: epidemiology, pathogenesis and management [ J ]. Curr Opin Obstet Gynecol, 2010,22:21-29.
5Homesley HD, Filiaci V, Markman M, et al. Phase III trial of ifosfamide with or without paclitaxel in advanced uterine carcinosarcoma: a Gynecologic Oncology Group Study [ J ]. J Clin Oncol,2007,25 : 526 -531.
6Powell MA, Filiaci VL, Rose PG, et al. Phase II evaluation of paclitaxel and carboplatin in the treatment of carcinosarcoma of the uterus: a Gynecologic Oncology Group study [ J ]. J Clin Oncol. 2010.28 : 2727 -2731.
7Creasman WT, Henderson D, Hinshaw W, et al. Estrogen replacement therapy in the patient treated for endometrial cancer [ J ]. Obstet Gynecol, 1986,67:326-330.
8Lee RB, Burke TW, Park RC. Estrogen replacement therapy following treatment for Stage I endometriaI carcinoma [ J ]. Gynecol Oncol, 1990,36 : 189-191.
9Chapman JA, DiSaia PJ, Osann K, et al. Estrogen replacement in surgical stage I and II endometrial cancer survivors[ J]. Am J Obstet Gynecol, 1996,175 : 1195-1200.
10Chlebowski RT, Hendrix SL, Langer RD, et al. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women ;s Health Initiative Randomized Trial[ J]. JAMA, 2003,289:3243-3253.
